{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:51:30Z","timestamp":1793397090926,"version":"4.5.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"INca","award":["10573"],"award-info":[{"award-number":["10573"]}]},{"name":"Societe francaise de dermatologie"},{"name":"ARC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Resistances to immunotherapies remains a major hurdle towards a cure for melanoma in numerous patients. An increase in the mesenchymal phenotype and a loss of differentiation have been clearly associated with resistance to targeted therapies. Similar phenotypes have been more recently also linked to resistance to immune checkpoint therapies. We demonstrated here that the loss of MIcrophthalmia associated Transcription Factor (MITF), a pivotal player in melanocyte differentiation, favors the escape of melanoma cells from the immune system. We identified Integrin beta-like protein 1 (ITGBL1), a secreted protein, upregulated in anti-PD1 resistant patients and in MITF<jats:sub>low<\/jats:sub> melanoma cells, as the key immunomodulator. ITGBL1 inhibited immune cell cytotoxicity against melanoma cells by inhibiting NK cells cytotoxicity and counteracting beneficial effects of anti-PD1 treatment, both in vitro and in vivo<jats:italic>.<\/jats:italic> Mechanistically, MITF inhibited RUNX2, an activator of ITGBL1 transcription. Interestingly, VitaminD3, an inhibitor of RUNX2, improved melanoma cells to death by immune cells. In conclusion, our data suggest that inhibition of ITGBL1 might improve melanoma response to immunotherapies.<\/jats:p>","DOI":"10.1186\/s12943-020-01306-2","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T05:03:13Z","timestamp":1609995793000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9839-4332","authenticated-orcid":false,"given":"Yann","family":"Cheli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meri K.","family":"Tulic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najla","family":"El Hachem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Nottet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Jacquel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeva","family":"Gesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Strub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Bille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Picard-Gauci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Montaudi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume E.","family":"Beranger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Passeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Close","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corine","family":"Bertolotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Ballotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"key":"1306_CR1","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ejca.2017.06.028","volume":"83","author":"S Ugurel","year":"2017","unstructured":"Ugurel S, et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Eur J Cancer. 2017;83:247\u201357. https:\/\/doi.org\/10.1016\/j.ejca.2017.06.028.","journal-title":"Eur J Cancer"},{"key":"1306_CR2","doi-asserted-by":"publisher","first-page":"8755","DOI":"10.1038\/ncomms9755","volume":"6","author":"S Riesenberg","year":"2015","unstructured":"Riesenberg S, et al. MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment. Nat Commun. 2015;6:8755. https:\/\/doi.org\/10.1038\/ncomms9755.","journal-title":"Nat Commun"},{"key":"1306_CR3","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.15252\/emmm.201505971","volume":"8","author":"G Richard","year":"2016","unstructured":"Richard G, et al. ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors. EMBO Mol Med. 2016;8:1143\u201361. https:\/\/doi.org\/10.15252\/emmm.201505971.","journal-title":"EMBO Mol Med"},{"key":"1306_CR4","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.molmed.2016.04.008","volume":"22","author":"X Bu","year":"2016","unstructured":"Bu X, Mahoney KM, Freeman GJ. Learning from PD-1 resistance: new combination strategies. Trends Mol Med. 2016;22:448\u201351. https:\/\/doi.org\/10.1016\/j.molmed.2016.04.008.","journal-title":"Trends Mol Med"},{"key":"1306_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo W, et al. Genomic and Transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165:35\u201344. https:\/\/doi.org\/10.1016\/j.cell.2016.02.065.","journal-title":"Cell"},{"key":"1306_CR6","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.7150\/jca.20900","volume":"8","author":"R Li","year":"2017","unstructured":"Li R, et al. ITGBL1 predicts a poor prognosis and correlates EMT phenotype in gastric cancer. J Cancer. 2017;8:3764\u201373. https:\/\/doi.org\/10.7150\/jca.20900.","journal-title":"J Cancer"},{"key":"1306_CR7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3233\/CBM-190460","volume":"27","author":"J Song","year":"2020","unstructured":"Song J, Yang P, Lu J. Upregulation of ITGBL1 predicts poor prognosis and promotes chemoresistance in ovarian cancer. Cancer Biomark. 2020;27:51\u201361. https:\/\/doi.org\/10.3233\/CBM-190460.","journal-title":"Cancer Biomark"},{"key":"1306_CR8","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.biopha.2018.05.033","volume":"104","author":"X Qiu","year":"2018","unstructured":"Qiu X, et al. ITGBL1 promotes migration, invasion and predicts a poor prognosis in colorectal cancer. Biomed Pharmacother. 2018;104:172\u201380. https:\/\/doi.org\/10.1016\/j.biopha.2018.05.033.","journal-title":"Biomed Pharmacother"},{"key":"1306_CR9","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1007\/s13277-015-3919-8","volume":"37","author":"X Gan","year":"2016","unstructured":"Gan X, Liu Z, Tong B, Zhou J. Epigenetic downregulated ITGBL1 promotes non-small cell lung cancer cell invasion through Wnt\/PCP signaling. Tumour Biol. 2016;37:1663\u20139. https:\/\/doi.org\/10.1007\/s13277-015-3919-8.","journal-title":"Tumour Biol"},{"key":"1306_CR10","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.1158\/0008-5472.CAN-15-0240","volume":"75","author":"XQ Li","year":"2015","unstructured":"Li XQ, et al. ITGBL1 is a Runx2 transcriptional target and promotes breast cancer bone metastasis by activating the TGFbeta signaling pathway. Cancer Res. 2015;75:3302\u201313. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-0240.","journal-title":"Cancer Res"},{"key":"1306_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/eLife.06857","volume":"4","author":"P Laurette","year":"2015","unstructured":"Laurette P, et al. Transcription factor MITF and remodeller BRG1 define chromatin organisation at regulatory elements in melanoma cells. Elife. 2015;4:1. https:\/\/doi.org\/10.7554\/eLife.06857.","journal-title":"Elife"},{"key":"1306_CR12","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1006\/excr.2002.5474","volume":"274","author":"H Drissi","year":"2002","unstructured":"Drissi H, et al. 1,25-(OH)2-vitamin D3 suppresses the bone-related Runx2\/Cbfa1 gene promoter. Exp Cell Res. 2002;274:323\u201333. https:\/\/doi.org\/10.1006\/excr.2002.5474.","journal-title":"Exp Cell Res"},{"key":"1306_CR13","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1152\/physiolgenomics.00185.2007","volume":"34","author":"SB Petkova","year":"2008","unstructured":"Petkova SB, et al. Genetic influence on immune phenotype revealed strain-specific variations in peripheral blood lineages. Physiol Genomics. 2008;34:304\u201314. https:\/\/doi.org\/10.1152\/physiolgenomics.00185.2007.","journal-title":"Physiol Genomics"},{"key":"1306_CR14","doi-asserted-by":"publisher","first-page":"e1476817","DOI":"10.1080\/2162402X.2018.1476817","volume":"7","author":"F Bochen","year":"2018","unstructured":"Bochen F, et al. Vitamin D deficiency in head and neck cancer patients - prevalence, prognostic value and impact on immune function. Oncoimmunology. 2018;7:e1476817. https:\/\/doi.org\/10.1080\/2162402X.2018.1476817.","journal-title":"Oncoimmunology"}],"updated-by":[{"DOI":"10.1186\/s12943-021-01319-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T00:00:00Z","timestamp":1611705600000}}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-020-01306-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12943-020-01306-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-020-01306-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T07:04:01Z","timestamp":1611731041000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-020-01306-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1306"],"URL":"https:\/\/doi.org\/10.1186\/s12943-020-01306-2","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12943-021-01319-5","asserted-by":"object"}]},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,7]]},"assertion":[{"value":"15 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via the original article.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Human study protocol was approved by the CPP ethics committees from Nice (DC-2015*2531). Informed consent was obtained from all human subjects included in this study. Mouse experiments were performed at the Animal Facilities of the Mediterranean Centre of Molecular Medicine (C3M) and the university of Li\u00e8ge according to French and Belgian laws. All mouse experiments at the C3M have been approved by Institutional Animal Care and the local ethical committee (APAFIS#202001281422585_v4).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}